Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > March 19, 2020
Daily News
March 19, 2020
- (Update) Japan Approves Novartis’ SMA Gene Therapy Zolgensma; 15-20 Patients Expected Annually
March 19, 2020
- MHLW Issues COVID-19 Treatment Guide
March 19, 2020
- Japanese Drug Firms Providing APIs for NIID Screening for COVID-19: JPMA Survey
March 19, 2020
- Increase Copay for OTC-Like Drugs under New Mixed-Care Scheme: Professor
March 19, 2020
- Nipro Confirms Second Coronavirus Case, Again in Niigata
March 19, 2020
- Pancreatitis Drug Nafamostat Potentially Effective for COVID-19: Researchers
March 19, 2020
- RIMD, BIKEN, NIBIOHN Start Development of COVID-19 Vaccine/Test Technology
March 19, 2020
- Eiken Launches Novel Coronavirus Detection Reagent Kit
March 19, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…